Business Wire

Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress

Share

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1

CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6

This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment they received as part of their standard clinical care in a real-world setting.

The primary endpoints were overall survival (OS), progression free survival (PFS) and summary of best responses and secondary endpoints included safety profile and CT-P10 treatment pathways. At 30-months post-index, amongst patients taking first-line CT-P10, 67% (95% confidence interval [CI] 61.3–72.1) had not experienced disease progression, with 74% (95% CI 69.2–79.1) overall survival.Of the 382 patients observed, over three quarters initiated on CT-P10 achieved complete or partial response by 30 months, with 82% having recorded a complete response (n=312). Partial response was seen in 12% (n=46), no response or stable disease in 4% (n=16) and progressive disease in 2% (n=8).

CT-P10 also appeared to be generally well tolerated by patients, with adverse events (AEs) consistent with those reported for reference rituximab. Overall, 90% (n=351) of patients reported at least one AE (total AEs n=2,504); 65% (n=253) experienced a grade 3 or higher AE, and 28% (n=109) were recorded as definitely, probably, or possibly related to CT-P10.

“This is the first multi-country retrospective post-approval study to investigate the effectiveness and safety of CT-P10 treatment in patients with DLBCL in a real-world setting across Europe,” said Dr. Mark Bishton, Consultant Haematologist and Honorary Clinical Associate Professor at the University of Nottingham, School of Medicine. “Over three quarters of patients initiated on CT-P10 achieved complete or partial response by 30 months. The response rates, survival rates and overall safety profile for CT-P10 appears consistent with those reported for reference rituximab, which could support the use of CT-P10 in combination with chemotherapy as a therapeutic option for DLBCL.”

Celltrion Healthcare also presented real-world data on rapid infusion of CT-P10 in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL) at the EHA Updates-in-Hematology.7 The study was the first multi-country study to investigate the safety and effectiveness of rapid infusion of CT-P10 in a real-world setting. Safety results suggest that rapid infusion of CT-P10 was generally well tolerated, with only 10% (n=20; 95% CI: 6 – 15%) of patients experiencing an infusion-related reaction (IRR). The majority of IRRs were grade 1 or 2 (96%), with the most common IRR being fatigue (35% n=7/20 of the patients with index IRRs), followed by nausea (30% n=6/20) and vomiting (15% n=3/20). In terms of response, the majority of patients achieved a complete response (74% n=142/192) or partial response (22% n=42/192) over the 6-month observation period.

“The recommended protocol for rituximab infusion in Europe is a slow initial infusion rate with a gradual upward titration. Rapid infusion is often used in subsequent infusions for patients who had no serious complications related to the first infusion,” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “We are encouraged by the results of the study as Truxima has demonstrated a similar IRR rate to reference rituximab. This will allow informed, evidence-based decisions on cost-effective treatment strategy for patients with CLL or NHL.”

- ENDS -

Notes to Editors:

About diffuse large B-cell lymphoma (DLBCL)3,4,5,6

There are more than 60 different subtypes of non-Hodgkin’s lymphoma (NHL), however diffuse large B-cell lymphomas (DLBCLs) are the most common subtype accounting for 30-40% of adult NHLs. Global epidemiological data is limited, however it is thought that the incidence is 7 cases per 100,000 people.

DLBCL is an aggressive condition and it is common to find patients with advanced disease at the point of diagnosis. The most commonly exhibited symptom is one or more painless swellings, and other general symptoms include heavy sweating at night, high temperatures that arise with no obvious cause and weight loss. Of DLBCL patients, 30-40% are thought to relapse and 10% of patients have refractory disease. Patients with relapsed refractory DLBCL if left untreated have a life expectancy of 3 to 4 months.

About Truxima® (biosimilar rituximab)8,9

Truxima® is a mAb that targets CD20, a transmembrane protein found on the surface of most B-cells. By binding specifically to CD20, Truxima® depletes B-cells by three main mechanisms: induction of apoptosis, stimulation of CDC (complement-dependent cytotoxicity) and stimulation of ADCC (antibody-dependent cell-mediated cytotoxicity). Truxima® is approved in the EU for the treatment of patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. Truxima® is the first rituximab similar biotherapeutic product to be prequalified by the World Health Organization (May 2020).

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

References


1 Bishton. M., et al. Real World Clinical Effectiveness and Safety of CT-P10 in Patients with Diffuse Large B-Cell Lymphoma: Results from a European Non-Interventional Post Authorization Safety Study. EHA 2021, Abstract #EP529.

2 European Medicines Agency Summary of Product Characteristics (SmPC). Truxima. Available at https://www.ema.europa.eu/en/documents/product-information/truxima-epar-product-information_en.pdf Last accessed May 2021.

3 NHL subtypes. Leukemia & Lymphoma Society. Available at: https://www.lls.org/lymphoma/non-hodgkin-lymphoma/diagnosis/nhl-subtypes Last accessed May 2021.

4 Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014;3(1):66‐70. doi:10.4103/2278-330X.126531.

5 Vivek Kumar et al. Recent Advances in Diffuse Large B Cell Lymphoma. Available from: https://www.intechopen.com/books/hematology-latest-research-and-clinical-advances/recent-advances-in-diffuse-large-b-cell-lymphoma Last accessed May 2021.

6 Diffuse large B cell lymphoma. Cancer Research UK. Available at: https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/diffuse-large-B-cell-lymphoma Last accessed May 2021.

7 Celltrion Healthcare, data on file.

8 European Medicines Agency Summary of Product Characteristics (SmPC). Truxima. Available at https://www.ema.europa.eu/en/documents/product-information/truxima-epar-product-information_en.pdf Last accessed May 2021

9 First rituximab similar biotherapeutic products prequalified. World Health Organization. Available at: https://extranet.who.int/prequal/news/first-rituximab-biotherapeutic-products-prequalified Last accessed May 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:

Holly Barber
hbarber@hanovercomms.com
+44 (0) 7759 301620

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GlobalLogic Launches Collaborative Hub Based in Lumada Innovation Hub Tokyo28.9.2021 02:00:00 CEST | Press release

Hitachi, Ltd. (TSE: 6501, “Hitachi”) and GlobalLogic*1, a Hitachi Group Company, today announced the launch of a collaborative hub to promote digital transformation (DX) services in the Japanese market. Based in the Lumada Innovation Hub Tokyo*2, a co-creation base for Hitachi, this collaboration hub combines capabilities of GlobalLogic and Lumada. Delivering on the joint integration strategy, this partnership aims to jump-start GlobalLogic’s entry into Japan, and will accelerate business development for design-led Digital Engineering services of GlobalLogic, establishing a system to support customers in Japan starting from fiscal 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005848/en/ A workshop connecting “Lumada Innovation Hub Tokyo” and GlobalLogic's Design and Engineering Centers. (Photo: Business Wire) "The market demand for DX continues to grow at a fast pace, as global brands increasingly leverage digit

SpeeDx and SynGenis Partner for Custom Oligonucleotide Synthesis28.9.2021 00:00:00 CEST | Press release

SpeeDx Pty, Ltd. a developer of innovative molecular diagnostic solutions announced investment in SynGenis Pty Ltd., an experienced oligonucleotide manufacturer based in Western Australia. The partnership will bolster internal capacity of SpeeDx to support large-scale increases in manufacturing while developing and expanding sovereign capacity of important raw materials used in molecular diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005329/en/ In addition to securing local supply chain to strengthen sovereign capacity for critical diagnostics and a more robust national health infrastructure, SpeeDx investment in local industry serves to fast track the growth and reach of SynGenis in the global diagnostics market. (Graphic: Business Wire) “We have invested considerable resources into our production scale-up processes to support the increase in testing seen as a result of the global pandemic,” said Tom Lin,

Medidata Veterans Rama Kondru and Sastry Chilukuri Named co-CEOs27.9.2021 23:00:00 CEST | Press release

Medidata, a Dassault Systèmes company, recently named Rama Kondru and Sastry Chilukuri co-CEOs. Both are Medidata veterans, with Chilukuri as the founding president of Medidata Acorn AI and Kondru as executive vice president and chief technology officer. Collaborating as CEOs will be nothing new for these industry leaders, having also partnered in roles prior to joining Medidata. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005812/en/ Medidata co-CEOs Sastry Chilukuri and Rama Kondru (l, r) (Photo: Business Wire) Chilukuri commented: “The life sciences industry is undergoing a sea change spurred by biological and technological innovation. We at Medidata are committed to being a trusted partner who helps customers deploy cutting-edge technology, data and AI to solve the impossible for patients.” Kondru commented: "We are excited to build the next chapter of Medidata around three critical pillars: a unified platform co

Next-Generation Arize Element® L1000 Enables Efficient Growth at an Industrial Scale27.9.2021 20:06:00 CEST | Press release

GE Current, a Daintree company, today introduced the next generation of the Arize Element L1000, a top light for commercial greenhouses and indoor farms. The next generation features three models with expanded spectral options, a high photon flux of up to 2,350 μmol/s, high efficacy levels of up to 3.6 µmol/J and is proudly assembled in the heart of Appalachia. “We set out to engineer the world’s most rugged and durable light fixture for commercial agriculture, thanks to our 20-plus years of LED fixture design experience combined with over 65 years of manufacturing excellence and scale in Hendersonville, North Carolina,” said Mike Doss, Current’s VP of Specialty. “We’ve improved the Element in every possible way, from light intensity to efficacy, and now it is proudly assembled in the Appalachians.” The Element family now features eight spectral options in three all-new models: L1000: The L1000 is a flexible, all-purpose fixture, with a PPF of up to 1900 µmol/s at 3.3 µmol/J. L1000 HE:

Creative Artists Agency to Acquire ICM Partners27.9.2021 19:00:00 CEST | Press release

Leading entertainment and sports agency Creative Artists Agency (CAA) announced today the execution of a definitive agreement to acquire ICM Partners (ICM), one of the world’s premier entertainment and sports agencies, to drive broader and more inclusive representation as their clients, their work, and their brands shape culture. “Today’s storytellers, athletes, thought-leaders, and trend-setters who can move, inspire, and attract large, global audiences have unprecedented opportunity and ability to achieve their goals and aspirations,” said CAA’s Bryan Lourd, Kevin Huvane, and Richard Lovett. “The strategic combination of CAA and ICM bolsters our collective resources, expertise, and relationships to deliver even more opportunities for our world-class clients to build their careers and their brands across multiple disciplines and platforms in an evolving marketplace. Our strong financial position enables us to continue to expand and diversify our businesses, with service and representa

teamLab Planets in Tokyo Opens a Dining Experience, an Art Space, and a Flower Shop on October 827.9.2021 18:00:00 CEST | Press release

teamLab Planets TOKYOin Toyosu, Tokyo welcomes “Vegan Ramen UZU Tokyo” from Kyoto; a new artwork space; and a flower shop where visitors can take home the orchids used in one of the museum’s artworks. “Vegan Ramen UZU Kyoto” opened in Kyoto in March of 2020, becoming hugely popular with hour-long wait times. At “Vegan Ramen UZU Tokyo,” vegan ramen can be enjoyed in the Reversible Rotation - Non-Objective Space or Table of Sky and Fire artwork spaces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005038/en/ Soy Sauce Vegan Ramen (Photo: Business Wire) There will also be a new flower shop, “teamLab Flower Shop & Art,” where visitors can take home orchids used in the artwork Floating Flower Garden: Flowers and I are of the Same Root, the Garden and I are One, in which visitors become one with over 13,000 orchids. All of these facilities open on Friday, October 8 to the public, not just to teamLab Planets museumgoers. Veg

Altasciences Continues Building Expansion with Additional Location in Philadelphia27.9.2021 16:05:00 CEST | Press release

Altasciences today announced the continued expansion of their formulation, manufacturing, and analytical services facilities in Philadelphia, PA. Altasciences, an integrated drug development solution company offering pharmaceutical and biotechnology companies worldwide a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services, launched a second building project to increase its capacity and meet the ever-growing needs of its clients. Altasciences’ first warehouse expansion started earlier this year and is expected to be ready for use by the end of 2021. The 35,000-square-foot space, acquired in December 2020, is directly adjacent to Altasciences’ existing facility. The new space, with its 24-foot ceilings, will be configured to include a ~8,750-square-foot warehouse, a ~8,750-square-foot Grade C/D manufacturing area, and a 17,500-square-foot client-dedicated cGMP manufacturing area. In addition, Altascienc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom